Kymera Therapeutics reports Q2 2025 results, plans call on August 11.
PorAinvest
lunes, 4 de agosto de 2025, 7:02 am ET1 min de lectura
KYMR--
Kymera Therapeutics is a biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. The company is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with immunological diseases. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years [2].
Investors and financial professionals are encouraged to register for the video call or view the livestreamed webcast via the provided link. A replay of the webcast will be archived and available following the event. For more information about Kymera’s science, pipeline, and people, please visit the company’s website or follow them on X or LinkedIn.
References:
[1] https://www.stocktitan.net/news/KYMR/kymera-therapeutics-to-report-second-quarter-2025-financial-results-za29t21v5aby.html
[2] https://www.kymeratx.com
• Kymera Therapeutics reports Q2 2025 financial results on August 11, 2025 • 8:30 a.m. ET video conference call and webcast to follow • Registration link: www.kymeratx.com/investors • Replay of webcast available after the event • Kymera is a clinical-stage biotech company pioneering targeted protein degradation • Developing medicines for critical health problems and improving patients' lives • Focusing on disease targets and pathways inaccessible with conventional therapies.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 11, 2025. The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Interested parties can register for the video call and access the webcast through a provided link or by visiting the "News and Events" section in the Investors area of Kymera's website [1].Kymera Therapeutics is a biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. The company is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with immunological diseases. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years [2].
Investors and financial professionals are encouraged to register for the video call or view the livestreamed webcast via the provided link. A replay of the webcast will be archived and available following the event. For more information about Kymera’s science, pipeline, and people, please visit the company’s website or follow them on X or LinkedIn.
References:
[1] https://www.stocktitan.net/news/KYMR/kymera-therapeutics-to-report-second-quarter-2025-financial-results-za29t21v5aby.html
[2] https://www.kymeratx.com
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios